RxDoctor Payments Data

Ricki Pollycove

Gynecology · San Francisco, CANPI 1013097013

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,352 of the $35,535 with a category attached, or 74.2%. Astellas Pharma US Inc accounts for 63.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $18,994 and has fallen 61.1% since, to $7,388 in 2025. Among gynecology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,535in general payments, 2019–2025

Across 124 payments — averaging $286.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$23K
  • Pfizer$5K
  • Ascend Therapeutics US, LLC$4K
  • Bayer$2K
  • Astellas Pharma Global Development$441
  • Mayne Pharma Commercial LLC$349
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$1,5004%
  • Speaking & faculty fees$26,35274%
  • Travel & lodging$3,66410%
  • Food & beverage$3,65210%
  • Education$3581%
  • Gifts$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,535 in reported general payments places this provider in the 95th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
FemringEstradiol Acetate90$68,149
Estradiol (Twice Weekly)Estradiol372$35,584
MinivelleEstradiol37$15,282
Estradiol123$13,464
ImvexxyEstradiol31$9,968
ProgesteroneProgesterone, Micronized181$7,368
PremarinEstrogens, Conjugated16$7,102
DottiEstradiol62$6,849
EstringEstradiol12$6,209
LyllanaEstradiol58$5,090
Vivelle-DotEstradiol23$4,735
ValacyclovirValacyclovir Hcl33$2,649
YuvafemEstradiol14$2,101
SynthroidLevothyroxine Sodium23$1,729
Zolpidem Tartrate14$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Millicent US IncFemring$19$68,14990 claims
PfizerPremarin, Estring$4,820$13,31128 claims
Therapeuticsmd, Inc.Imvexxy$191$9,96831 claims
AbbVieSynthroid, Armour Thyroid$179$2,74135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 gynecology providers in California.

Other gynecology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →